Operating
Idexx Laboratories·Cash Flow Statement·13 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net income | $203.3M | $232.8M | $216.1M | $242.7M | $294M | $274.6M | $248.2M | $278.4M |
| Net cash from operating activities | $248.3M | $220.1M | $262M | $238M | $185.7M | $402.3M | $355.8M | $266.2M |
| Change in accounts receivable | $29.1M | — | — | $45.2M | $29.6M | $7.7M | — | $56.8M |
| Depreciation and amortization | $32.2M | $34.1M | $33.7M | $34.1M | $35.8M | $36.6M | $38.7M | $37.7M |
| Stock-based compensation | $15.7M | $15.9M | $14.3M | $14.6M | $14.9M | $14.4M | $16.1M | $16.3M |
| Deferred income taxes | -$19.5M | -$6.8M | — | $3.9M | $2.5M | $93.2M | $31.5M | $13.9M |
| Change in accounts payable | $8.3M | — | $5.7M | -$8.1M | -$4M | — | -$3.6M | $11.2M |
| Impairment charges | — | — | — | $0 | $0 | $0 | — | $5M |
| Asset write-downs | — | — | — | $0 | $0 | $0 | — | $5M |
| Provision for Loan, Lease, and Other Losses | $2.2M | $1.3M | $1.8M | $2.9M | $1.5M | $1.6M | $2.5M | $3.9M |
| Provision for credit losses | $2.2M | $1.3M | $1.8M | $2.9M | $1.5M | $1.6M | $2.5M | $3.9M |
| Change in inventories | $3.8M | $18.5M | $3.2M | -$2.2M | $6.2M | — | — | -$2.2M |
| Other working capital changes | $58K | $67K | $434K | $456K | $1M | $1.8M | $1.8M | $695K |